2008 ASCO Genitourinary Cancers Symposium: Updates in the Management of Prostate and Kidney Cancers - CME
C. Dean Buckner, MD

ASCO 2007: Targeted Therapy and Renal Cell Carcinoma: Are We Making Progress?
Robert J. Amato, DO, Weill Medical College of Cornell University, University of Texas Health Science Center - Houston, The Methodist Hospital Research Institute, Houston, Texas

ASCO 2007: Update on the Management of Genitourinary Malignancies
Nancy A. Dawson, MD – Lombardi Comprehensive Cancer Center

Current Topics

Radiofrequency Ablation Effective For Small Renal Cell Carcinoma and Other Masses (3/11/2010)
Researchers from the M. D. Anderson Cancer Center have reported that radiofrequency ablation (RFA) is effective treatment for patients with renal masses, including renal cell carcinoma (RCC). The details of this study were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium March 5-7 in San Francisco.

Recent Results of High-dose Proleukin® for Metastatic Renal Cell Carcinoma Reported (3/10/2010)
Researchers involved in a U.S. multicenter trial (Cytokine Working Group) have reported that high-dose Proleukin® (aldesleukin, interleukin-2, IL-2) results in a higher response rate in patients with metastatic renal cell carcinoma (MRCC) than historically reported. The details of this study were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, March 5-7, in San Francisco.

Avastin® Not Contraindicated in Patients with CNS Metastases (3/8/2010)
Researchers from France have reported that patients with central nervous system (CNS) metastases have similar rates of whether or not they receive Avastin® (bevacizumab). The details of this study appeared in the January 2010 issue of Clinical Cancer Research.

Cryoablation Effective for Renal Cell Carcinoma (2/23/2010)
Two studies in the in the March 2010 issue of the Journal of Urology suggest that stereotactic percutaneous cryoablation and laparoscopic renal cyroablation are effective treatments for selected patients with renal cell carcinoma (RCC).

Neoadjuvant Nexavar® in Patients with Renal Cell Carcinoma Is Well Tolerated (2/18/2010)
Researchers from the University of North Carolina have reported that neoadjuvant Nexavar® (sorafenib) before nephrectomy is well tolerated in patients with Stage II or higher renal cell carcinoma (RCC). The details of this study appeared in an early online publication in the Journal of Clinical Oncology.